Kynam Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-302,500
Closed -$21.6M – 34
2025
Q1
$21.6M Buy
+302,500
New +$14.7M 1.82% 17

Kynam Capital Management's SLNO Position: Q2 2026 in Review

Kynam Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 560,000 shares — an estimated $18.7M sold.

Kynam Capital Management first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $18.7M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Kynam Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kynam Capital Management sold 560,000 Soleno Therapeutics shares in Q2 2026, an estimated $18.7M.
  • Kynam Capital Management first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
  • Kynam Capital Management's Soleno Therapeutics position peaked at $18.7M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.